MARKET

OGN

OGN

ORGANON & CO
NYSE
24.07
+0.67
+2.86%
After Hours: 24.29 +0.22 +0.91% 19:56 10/03 EDT
OPEN
23.66
PREV CLOSE
23.40
HIGH
24.27
LOW
23.34
VOLUME
2.39M
TURNOVER
0
52 WEEK HIGH
39.48
52 WEEK LOW
23.33
MARKET CAP
6.12B
P/E (TTM)
5.54
1D
5D
1M
3M
1Y
5Y
Organon Canada reinforces the need to raise awareness and access for contraception methods with nearly half of pregnancies unplanned
On World Contraception Day (September 26), Organon (NYSE: OGN), a global women's health company, is launching Act with Her, a multi-faceted approach to help tackle the global health issue of unintended pregnancies (UIPs) and to improve access to contracept...
CNW Group · 09/26 11:00
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
Benzinga · 09/13 13:20
Organon upgraded at Piper on strength of established brands segment
The shares of Organon & Co. (NYSE:OGN) traded higher in the mornin...
Seekingalpha · 09/06 14:42
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades
Benzinga · 09/06 14:09
This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%
Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading.
Benzinga · 09/06 12:16
Piper Sandler Upgrades Organon to Overweight, Lowers Price Target to $34
Piper Sandler analyst David Amsellem upgrades Organon (NYSE:OGN) from Neutral to Overweight and lowers the price target from $37 to $34.
Benzinga · 09/06 08:53
Piper Sandler Upgrades Organon & Co. to Overweight From Neutral, Adjusts Price Target to $34 From $37
Piper Sandler Upgrades Organon & Co. to Overweight From Neutral, Adjusts Price Target to $34 From $37
MT Newswires · 09/06 06:34
This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'
Benzinga · 08/30 18:56
More
About OGN
Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates approximately six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Webull offers kinds of Organon & Co stock information, including NYSE:OGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGN stock methods without spending real money on the virtual paper trading platform.